Search Result

Isoforms Recommended:	D₂ Receptor

Results for "

rat D2 receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (21) Adrenergic Receptor (1) Calcium Channel (1) COX (2) Dopamine Receptor (43) Dopamine Transporter (1) Drug Derivative (1) Drug Metabolite (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (2) iGluR (1) Isotope-Labeled Compounds (1) mAChR (1) nAChR (1) NO Synthase (2) Prostaglandin Receptor (3) Reference Standards (7) Sigma Receptor (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (1) Endocrinology (5) Inflammation/Immunology (2) Neurological Disease (42)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14542

Ziprasidone 3 Publications Verification CP-88059	5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist . Ziprasidone mesylate trihydrate has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-10435A

SKF-82958 hydrobromide 4 Publications Verification (±)-SKF-82958 hydrobromide; Chloro-APB hydrobromide	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-17407

Ziprasidone hydrochloride monohydrate 3 Publications Verification CP 88059 hydrochloride monohydrate	5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (CP-88059) hydrochloride monohydrate is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone hydrochloride monohydrate has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-14542A

Ziprasidone hydrochloride 3 Publications Verification CP-88059 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (CP-88059) hydrochloride is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone hydrochloride has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-100656

Desmethyl cariprazine	Dopamine Receptor 5-HT Receptor	Neurological Disease
Desmethyl cariprazine is a major active metabolite of cariprazine, with activities at human dopamine receptors and serotonin receptors, showing a pEC₅₀ of 8.90 at human D2 receptors, a pEC₅₀ of 8.09 at D3 receptors, and a pEC₅₀ of 6.28 at 5-HT_1A receptors. Desmethyl cariprazine inhibits forskolin-induced cAMP production at D2, D3 and 5-HT_1A receptors, and suppresses serotonin-induced Ca ²⁺ release at 5-HT_2B receptors. Desmethyl cariprazine is applicable to research related to schizophrenia, bipolar disorder type I and bipolar disorder.

HY-107969

Haloperidol decanoate	Dopamine Receptor COX NO Synthase	Neurological Disease Cancer
Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-110000

(+)-PD 128907 hydrochloride	Dopamine Receptor	Neurological Disease
(+)-PD 128907 hydrochloride is a selective dopamine *D₂/D₃* receptor agonist, with K_is of 1.7, 0.84 nM for human and rat D₃ receptors, 179, 770 n M for human and rat D₃ receptors, respectively.

HY-100820

Sarizotan 1 Publications Verification EMD 128130	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-130344

SKF 83959 1 Publications Verification	Dopamine Receptor Sigma Receptor	Neurological Disease
SKF83959 is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 can be used for the research of Alzheimer's disease and depression .

HY-100658

Didesmethyl cariprazine	5-HT Receptor Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D₂ and D₃ receptors, full agonist at the 5-HT_1A receptor, and antagonist at the human 5-HT_2B receptor (K_i: 1.41 nM (human D_2L), 0.056 nM (human D₃), 1.7 nM (human 5-HT_1A), 0.52 nM (human 5-HT_2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons .

HY-106584

Mosapramine Clospipramine	Drug Derivative Dopamine Receptor 5-HT Receptor	Neurological Disease
Mosapramine (Clospipramine) is an orally active antipsychotic agent and one of the metabolites of Clocapramine (HY-B2073) after oral absorption. Mosapramine exerts its effects by specifically binding to striatal dopamine D2 receptors and frontal lobe 5-HT2 receptors, with a *D2/5-HT2* receptor occupancy ratio of 7.4. Mosapramine induces typical neuropharmacological responses in rat brain regions, including extrapyramidal symptoms, hyperprolactinemia, increased salivation, constipation, and upregulated Fos protein expression. Mosapramine also features a reduced incidence of weight loss. Mosapramine is applicable to research related to schizophrenia .

HY-14840

Phenylpiracetam Carphedon	nAChR Dopamine Transporter GABA Receptor iGluR	Neurological Disease
Phenylpiracetam (Carphedon) is a positive allosteric modulator of nicotinic acetylcholine receptors (nAChR) with an IC₅₀ of 5.86 μM. Phenylpiracetam is applicable to studies on scopolamine (Scopolamine) (HY-N0296)-induced amnesia, depression and immune stress .

HY-P0079

Neuromedin N 2 Publications Verification Neuromedin N (rat, mouse, porcine, canine)	Dopamine Receptor	Neurological Disease
Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes.

HY-12783A

SCH 50911	GABA Receptor	Neurological Disease
SCH 50911 is a selective, orally active, blood-brain barrier permeable GABA-B receptor (GABA-B Receptor) antagonist with an IC₅₀ of 1.1 μM in rats. SCH 50911 blocks baclofen-induced antitussive effects, regulates neuronal firing and GABA release. SCH 50911 promotes spontaneous seizures during withdrawal in ethanol-dependent rats, alters reward-related neurotransmission, and reduces or suppresses lever responding and self-administration behaviors of alcohol and sucrose in rats. SCH 50911 is applicable to research related to ethanol withdrawal syndrome, absence epilepsy and alcohol use disorder .

HY-106432A

Sabcomeline hydrochloride SB-202026 hydrochloride; Memric hydrochloride	mAChR Dopamine Receptor	Neurological Disease
Sabcomeline (SB-202026; Memric) hydrochloride is a muscarinic receptor agonist capable of crossing the blood-brain barrier. Sabcomeline hydrochloride exhibits affinity for all hM1 to hM5 subtypes (pK_i=6.72-7.23), and shows near-full agonism at the hM3 receptor, inducing extracellular acidification. Sabcomeline hydrochloride alters the binding kinetics of dopamine D2 receptors through neural network regulation. Sabcomeline hydrochloride also causes minimal cardiovascular changes, effectively reverses spatial memory deficits in rodents and induces conditioned taste aversion. Sabcomeline hydrochloride is an important tool compound in studies of Alzheimer's disease and related neurodegenerative diseases .

HY-W742532

ETH-LAD N-Ethyl-nor-LSD	5-HT Receptor Dopamine Receptor	Neurological Disease
ETH-LAD (N-Ethyl-nor-LSD) is an activator for 5-HT2A receptor with K_i of 5.1 nM. ETH-LAD exhibits affinity for *dopamine receptor* D1 and dopamine receptor D2 with K_i** of 22.1 nM and 4.4 nM. ETH-LAD acts as psychoactive substance in rat model .

HY-13213

AM211 AM211 free acid	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AM211 is a potent, selective and orally bioavailable *prostaglandin D2 (PGD2) receptor* type 2 (DP2) antagonist, with IC₅₀*s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat* DP2, respectively.

HY-103409

ABT-724 trihydrochloride	Dopamine Receptor	Neurological Disease
ABT-724 trihydrochloride is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM), and has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-103412

SKF 83959 hydrobromide 1 Publications Verification	Dopamine Receptor Sigma Receptor	Neurological Disease
SKF83959 hydrobromide is a potent and selective dopamine D₁-like receptor partial agonist. SKF83959 hydrobromide K_i values for rat D₁, D₅, D₂ and D₃ receptors are 1.18, 7.56, 920 and 399 nM, respectively. SKF83959 hydrobromide is a potent allosteric modulator of sigma (σ)-1 receptor. SKF83959 hydrobromide belongs to benzazepine family and has improvements on cognitive dysfunction. SKF83959 hydrobromide can be used for the research of Alzheimer's disease and depression .

HY-P10405A

TAT-D1 peptide acetate	Dopamine Receptor	Neurological Disease
TAT-D1 peptide acetate is a dopamine *D1-D2* receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-13706

CAY10471 Racemate TM30089 Racemate	Prostaglandin Receptor	Endocrinology Cancer
CAY10471 Racemate (TM30089 Racemate) is a potent and highly selective *prostaglandin D2 receptor* CRTH2 antagonist, with a K_i** of 0.6 nM for hCRTH2, selective over human thromboxane A2 receptor TP (K_i, >10000 nM) or PGD2 receptor DP (K_i, 1200 nM). CAY10471 Racemate also has effect on mouse and rat orthologs of CRTH2 .

HY-14330

ABT-724	Dopamine Receptor	Neurological Disease
ABT-724, a chemical probe, is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM). ABT-724 has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a dopamine *D1-D2* receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-10435

SKF-82958 (±)-SKF-82958; Chloro-APB	Dopamine Receptor	Neurological Disease
SKF-82958 ((±)-SKF 82958) is a dopamine D1 receptor full agonist (K_0.5=4 nM), displays selective for D1 over D2 receptors (K_0.5=73 nM). SKF-82958 induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC₅₀=491 nM) .

HY-14542C

Ziprasidone mesylate CP-88059 mesylate	5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (CP-88059) mesylate is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone mesylate has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-14542B

Ziprasidone mesylate trihydrate CP-88059 mesylate trihydrate	5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (CP-88059) mesylate trihydrate is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone mesylate trihydrate has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-114618

S33084	Dopamine Receptor	Neurological Disease
S33084 is a dopamine D(3)-receptor antagonist with the _pK_i values of 8.72, 8.62 and 6.82 of cloned rat dopamine D3 receptor, native rat dopamine D3 and D2 receptor .

HY-100820B

Sarizotan dihydrochloride EMD 128130 dihydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan dihydrochloride (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820A

Sarizotan hydrochloride EMD 128130 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan hydrochloride is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan hydrochloride (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-101641

NRA-0160	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease Endocrinology
NRA-0160 is a selective dopamine D4 receptor antagonist, with a K_i value of 0.48 nM and with negligible affinity for dopamine D2 receptor (K_i: >10000 nM), D3 receptor (K_i: 39 nM), rat 5-HT2A receptor (K_i: 180 nM) and rat α1 adrenoceptor (K_i: 237 nM).

HY-111066

JNJ-37822681	Dopamine Receptor	Others
JNJ-37822681 is a fast dissociating D2 antagonist with activity in inhibiting schizophrenia. JNJ-37822681 has high specificity for D2 receptors and is effective in animal models, inducing increased levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibiting antidepressant activity in the mouse tail suspension test, while having a good brain distribution and lower prolactin release.

HY-100820R

Sarizotan (Standard) EMD 128130 (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (Standard) is the analytical standard of Sarizotan. This product is intended for research and analytical applications. Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100539

PD 128907	Dopamine Receptor	Others
PD 128907 is a D3 receptor ligand with activities of activating dopamine receptors, inhibiting cell firing, and inhibiting dopamine release. The active (+) enantiomer of PD 128907 has high affinity and selectivity for rat D3 dopamine receptors. PD 128907 inhibits cell firing in the ventral tegmental area and substantia nigra pars compacta with EC₅₀ values of 33nM and 38nM, respectively. PD 128907 also inhibits dopamine release in the caudate putamen with an EC₅₀ of 66nM. However, the selective D2 receptor antagonist L-741,626 has high affinity for receptors activated by PD 128907, indicating that the effects of PD 128907 are more likely on D2 autoreceptors rather than D3 dopamine receptor subtypes.

HY-114578

PD 118717	Dopamine Receptor 5-HT Receptor	Neurological Disease
PD 118717 is a selective *dopamine (DA) D-2* autoreceptor agonist. PD 118717 has significant affinity for 5-HT1A** but not 5-HT1B and 5-HT2 receptors. PD 118717 is active in antagonizing the tau-Butyrolactone-induced accumulation of dopa in rat striatum and mesolimbic regions. PD 118717 exhibits an antipsychotic-like profile .

HY-171328

RG-15	Dopamine Receptor	Neurological Disease
RG-15 is the orally active antagonist for dopamine receptor that exhibits goof affinity to human D2 receptor and human D3 receptor with pK_i of 8.23 and 10.49. RG-15 inhibits dopamine-stimulated [ ³⁵S]GTPγS binding with IC₅₀ of 21.2 nM (rat striatal membranes), 36.7 nM (mouse A9 cells expressing human D2L receptors) and 7.2 nM (CHO cells expressing human D3 receptors). RG-15 increases the turnover and biosynthesis of dopamine in mouse striatum and olfactory bulb, exhibiting antipsychotic activity .

HY-10435AR

SKF-82958 hydrobromide (Standard) (±)-SKF-82958 hydrobromide (Standard); Chloro-APB hydrobromide (Standard)	Reference Standards Dopamine Receptor	Neurological Disease
SKF-82958 (hydrobromide) (Standard) is the analytical standard of SKF-82958 (hydrobromide). This product is intended for research and analytical applications. SKF-82958 ((±)-SKF 82958) hydrobromide is a dopamine D1 receptor full agonist (K0.5=4 nM), displays selective for D1 over D2 receptors (K0.5=73 nM). SKF-82958 hydrobromide induces dopamine D1 receptor-dependent adenylate cyclase activity in rat striatal membranes (EC50=491 nM) .

HY-17407R

Ziprasidone hydrochloride monohydrate (Standard) CP 88059 hydrochloride monohydrate (Standard)	Reference Standards 5-HT Receptor Dopamine Receptor	Neurological Disease
Ziprasidone (hydrochloride monohydrate) (Standard) is the analytical standard of Ziprasidone (hydrochloride monohydrate). This product is intended for research and analytical applications. Ziprasidone (CP-88059) hydrochloride monohydrate is an orally active combined 5-HT and dopamine receptor antagonist . Ziprasidone hydrochloride monohydrate has affinities for Rat D₂ (K_i=4.8 nM), 5-HT_2A (K_i=0.42 nM) and 5-HT_1A (K_i=3.4 nM) .

HY-107969R

Haloperidol decanoate (Standard)	Dopamine Receptor Reference Standards COX NO Synthase	Neurological Disease
Haloperidol decanoate (Standard) is the analytical standard of Haloperidol decanoate. This product is intended for research and analytical applications. Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-14542R

Ziprasidone (Standard) CP-88059 (Standard)	5-HT Receptor Dopamine Receptor Reference Standards	Neurological Disease
Ziprasidone (Standard) is the analytical standard of Ziprasidone. This product is intended for research and analytical applications. Ziprasidone (CP-88059), an orally active antipsychotic agent, is a combined 5-HT and dopamine receptor antagonist . Ziprasidone mesylate trihydrate has affinities for Rat D2 (Ki=4.8 nM), 5-HT2A (Ki=0.42 nM) and 5-HT1A (Ki=3.4 nM) .

HY-100057

BMY 28674 6-Hydroxybuspirone; 6'-Hydroxybuspirone; BMS 528215	5-HT Receptor Drug Metabolite Dopamine Receptor	Neurological Disease
BMY 28674 (6-Hydroxybuspirone) is the active metabolite of the anxiolytic buspirone (HY-B1115A) and is metabolized by CYP3A4.4. BMY 28674 binds to the serotonin (5-HT) receptor subtype 5-HT1A in the rat hippocampus and dorsal raphe (EC₅₀s are 4 and 1 μM, respectively) and is an antagonist of dopamine D2, D3, and D4 receptors (IC₅₀s are 3.1, 4.9, and 0.85 μM, respectively). BMY 28674 also inhibits organic cation transporter 1 (OCT1), OCT2, and OCT3 expressing human transporters in S2 proximal tubule cells in a concentration-dependent manner.

HY-123189

LY 171859	Dopamine Receptor	Neurological Disease
LY 171859 is a D2 receptor agonist with significant reductase activity. LY 171859 exhibits enzymatic activity in the cytoplasm of liver, lung, and kidney, and also contains significant reductase activity in rat and human blood. LY 171859 has higher hepatic reductase activity in guinea pigs, followed by hamsters, rabbits, rats, and mice. The substrate of LY 171859 shows an apparent Km of 5.6 μM. The reduction reaction of LY 171859 is NADPH-dependent with an apparent Km of 14.8 μM. Only the A-side hydrogen of NADPH is incorporated in the reduction product of LY 171859. The reaction of LY 171859 is inhibited by cyanide and thiol reagents, and phenobarbital does not induce its activity in rats .

HY-N15735

Cimicifugic acid D 2-Caffeoylpiscidic acid	Calcium Channel	Cardiovascular Disease
Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyltartaric acid ester that induces vasodilation of precontracted rat aortic strips and endothelium-independent relaxation mechanism. Cimicifugic acid D inhibits extracellular Ca ²⁺ influx through receptor-operated Ca ²⁺ channels (ROC) in Norepinephrine (HY-13715)-induced contraction of rat aortic strips, without affecting voltage-dependent Ca ²⁺ channels (VDC) or K ⁺-induced contractions .

HY-131531A

5-OH-DPAT 5-Hydroxy-DPAT	Dopamine Receptor	Endocrinology
5-OH-DPAT (5-Hydroxy-DPAT) is a potent and selective dopamine D2-receptor agonist lacking effects at 5-HT receptors. 5-OH-DPAT produces a moderate facilitation of the male rat sexual behavior .

HY-13213A

AM211 sodium	Prostaglandin Receptor	Inflammation/Immunology Endocrinology
AM211 sodium is a potent, selective and orally bioavailable *prostaglandin D2 (PGD2) receptor* type 2 (DP2) antagonist, with IC₅₀*s of 4.9 nM, 7.8 nM, 4.9 nM, 10.4 nM for human, mouse, guinea pig, and rat* DP2, respectively.

HY-103409R

ABT-724 trihydrochloride (Standard)	Reference Standards Dopamine Receptor	Neurological Disease
ABT-724 trihydrochloride (Standard) is the analytical standard of ABT-724 trihydrochloride (HY-103409). This product is intended for research and analytical applications. ABT-724 trihydrochloride is a potent and highly selective dopamine D4 receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D4 receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D4 (EC₅₀ of 14.3 nM) and the ferret D4 receptor (EC₅₀ of 23.2 nM), and has no effect on dopamine D1, D2, D3, or D5 receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-100658S

Didesmethyl cariprazine-d8	Isotope-Labeled Compounds 5-HT Receptor Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine-d₈ is the deuterium labeled Didesmethyl cariprazine (HY-100658). Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (K_i: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons.

HY-100658R

Didesmethyl cariprazine (Standard)	5-HT Receptor Reference Standards Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine (Standard) is the analytical standard of Didesmethyl cariprazine (HY-100658). This product is intended for research and analytical applications. Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (Ki: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons .

HY-182381

FLA-797	Dopamine Receptor	Neurological Disease
FLA-797 is a brain-penetrant dopamine D2 receptor blocker and very low affinity for dopamine D1 receptors. FLA-797 selectively binds to and blocks postsynaptic dopamine D2 receptors. FLA-797 induces catalepsy in male rats. FLA-797 blocks dopamine agonist-induced hypothermia in male rats. FLA-797 contributes marginally to the dopamine D2 receptor-blocking activity of Remoxipride (HY-101313) in male rats. FLA-797 does not mimic the atypical antipsychotic profile of Remoxipride. FLA-797 can be used for research on mental disorders .

HY-121675A

2-Bromo-LSD D-Tartrate BOL-148 D-Tartrate; Bromolysergide D-Tartrate	5-HT Receptor G protein-coupled Bile Acid Receptor 1	Neurological Disease
2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) is a blood-brain barrier-permeable 5-HT_2A partial agonist and competitive partial antagonist. 2-Bromo-LSD D-Tartrate acts as both a potent partial agonist (with an EC₅₀ of 0.81 nM for Gq dissociation) and a potent partial antagonist (with a K_B of 0.18 nM for Gq dissociation) at the 5-HT_2A receptor. 2-Bromo-LSD D-Tartrate exhibits partial agonist activity at multiple aminergic GPCRs, including 5-HT_2A. 2-Bromo-LSD D-Tartrate lacks 5-HT_2B agonist activity. 2-Bromo-LSD D-Tartrate induces dendritogenesis and spinogenesis. 2-Bromo-LSD D-Tartrate reverses the behavioral effects of chronic stress and increases active coping behaviors in mice .

HY-183776

*Dopamine D3 receptor* agonist-2**	Dopamine Receptor	Others
Dopamine D3 receptor agonist-2 is a selective dopamine D3 receptor partial agonist with a K_i of 0.268 nM. Dopamine D3 receptor agonist-2 exhibits 29-fold selectivity over dopamine D2 receptor (K_i= 7.67nM) .

Cat. No.	Product Name	Target	Research Area

HY-P0079

Neuromedin N 2 Publications Verification Neuromedin N (rat, mouse, porcine, canine)	Dopamine Receptor	Neurological Disease
Neuromedin N is a potent modulator of dopamine D2 receptor agonist binding in rat neostriatal membranes.

HY-P10405A

TAT-D1 peptide acetate	Dopamine Receptor	Neurological Disease
TAT-D1 peptide acetate is a dopamine *D1-D2* receptor heterodimer inhibitor. TAT-D1 peptide acetate disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide acetate produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide acetate can be used in the research of psychostimulant addiction, depression and anxiety disorders .

HY-P10405

TAT-D1 peptide	Dopamine Receptor	Neurological Disease
TAT-D1 peptide is a dopamine *D1-D2* receptor heterodimer inhibitor. TAT-D1 peptide disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity, and exacerbates the expression of amphetamine-induced locomotor sensitization. TAT-D1 peptide produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety, and inhibits c-fos expression in the nucleus accumbens of rats. TAT-D1 peptide can be used in the research of psychostimulant addiction, depression and anxiety disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15735

Cimicifugic acid D 2-Caffeoylpiscidic acid	Ranunculaceae Phenols Polyphenols Plants Cimicifuga racemosa (L.) Nutt. Source Classification	Calcium Channel
Cimicifugic acid D (2-Caffeoylpiscidic acid) is a benzyltartaric acid ester that induces vasodilation of precontracted rat aortic strips and endothelium-independent relaxation mechanism. Cimicifugic acid D inhibits extracellular Ca ²⁺ influx through receptor-operated Ca ²⁺ channels (ROC) in Norepinephrine (HY-13715)-induced contraction of rat aortic strips, without affecting voltage-dependent Ca ²⁺ channels (VDC) or K ⁺-induced contractions .

Cat. No.	Product Name	Chemical Structure

HY-100658S

Didesmethyl cariprazine-d8

Didesmethyl cariprazine-d₈ is the deuterium labeled Didesmethyl cariprazine (HY-100658). Didesmethyl cariprazine is an orally active, BBB-permeable metabolite of Cariprazine (HY-14763). Didesmethyl cariprazine is a partial agonist at the D2 and D3 receptors, full agonist at the 5-HT1A receptor, and antagonist at the human 5-HT2B receptor (K_i: 1.41 nM (human D2L), 0.056 nM (human D3), 1.7 nM (human 5-HT1A), 0.52 nM (human 5-HT2B)). Didesmethyl cariprazine dose-dependently inhibits the spontaneous activity of rat midbrain dopaminergic neurons.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

rat D2 receptor

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products